Nicotine oral thin film has moved from novelty format to a procurement category with its own supply base and its own verification problems. Market Research Future valued the global nicotine oral dissolvable thin film market at USD 112.34 million in 2024 and projects it to reach USD 174.18 million by 2035. Grand View Research, using a wider scope that includes nicotine pouches, estimates the modern oral nicotine products market will reach USD 38.9 billion by 2033 at a 19.0% CAGR. The two figures measure different market boundaries and should not be blended, but both point to the same shift: oral formats are absorbing demand that previously went to combustible and device-based nicotine delivery.

For a buyer at the decision stage, the format question is already settled. The live question is whether the manufacturer behind a quotation can deliver a customized film, at a controlled dose, on a repeatable schedule, with documentation that holds up in a market-specific compliance review. That is a factory question rather than a product-page question, and it is the question this article works through using SENO's disclosed operational facts.

Why Factory Evidence Became a Procurement Requirement

Quotations from different nicotine film suppliers tend to look similar on paper: a stated strength, a dissolution time, a packaging format, a unit price. What separates programs that scale from programs that stall sits one level below the quotation, in installed capacity, in how dose consistency is proven, and in whether documentation is produced on request rather than on promise.

Three constraints drive this. The first is dose consistency. Because a film delivers nicotine through the oral mucosa as a single unit, variability between individual sheets is the dominant quality risk, and it is largely a manufacturing control problem rather than a formulation problem. The second is stability: thin films are sensitive to humidity and temperature, which makes moisture-barrier packaging and storage control part of product performance rather than logistics detail. The third is regulatory review. Formulations and labels must be adjusted per target market, and buyers selling into the United States and the European Union increasingly need a supplier able to prepare for PMTA or TPD pathways instead of improvising after an order is placed.

Read in that context, OEM/ODM claims become checkable. The rest of this article separates what SENO's operational data establishes from what a buyer still has to test.

What SENO's Facility Data Establishes

SENO is a nicotine oral thin film manufacturer backed by Xin Sino Technology (Shenzhen) Co., Ltd., a company established in 2025 and located in Shenzhen, Guangdong Province, China. SENO produces nicotine film and oral film and states that 100% of its output is export-oriented, serving markets including the EU, the USA, Canada, and Australia, alongside distributor relationships across Europe, North America, and the Middle East.

Two readings of this data matter for a procurement file, and neither should be skipped.

The capacity figure is a range, not a single commitment. A band of 12,000,000 to 50,000,000 strips per year behaves like a scheduling variable: the lower end represents the volume the plant states it can support as a baseline, while the upper end depends on product mix, film dimensions, and how many SKUs share the line at one time. Buyers should treat the range as a planning input and confirm throughput for their specific format during project scoping rather than assuming the ceiling.

The second reading is structural. A 20,000 m² facility run by approximately 30 employees points to a capital-intensive, automation-led production model rather than a labour-intensive one. For OEM buyers this produces two practical consequences. Consistency is more likely to come from equipment settings and process control than from operator skill, which is favourable for repeat orders. At the same time, engineering attention held by a 15-person R&D team is the scarcer resource in the relationship, so buyers running multiple customization programs in parallel should confirm how R&D time is allocated before locking a launch date.

How OEM/ODM Customization Is Actually Executed

Customization in this category is not a single service. It runs across three connected layers, and changing one generally forces re-validation of another.

1. Film dimensions and physical format

Film dimensions are adapted to fit a brand's intended pack, dispenser, or sachet configuration. Dimension changes are not cosmetic: the surface area of the film is a direct input into how quickly it hydrates and dissolves, so a dimension change normally requires the dissolution profile to be re-checked and re-documented before a batch is released.

2. Nicotine strength and dose control

Strength adjustment is the most frequently requested OEM/ODM change. Industry technical references describe oral nicotine thin films as typically built on hydrophilic polymers such as HPMC at 40–50% of film weight, dissolving within 15–30 seconds to bypass first-pass hepatic metabolism. SENO states dissolution within 30 seconds for its film. Dose precision is handled through film quantification technology with milligram-level error control per sheet, reinforced by batch consistency testing. Market-side evidence of how strength is expressed to regulators is visible in the United States, where SENO oral films are listed in the DailyMed / NIH drug label database at a 1.5% nicotine concentration, intended to relieve mental fatigue and alleviate withdrawal symptoms. That difference between a supplier's internal formulation capability and a market's permitted label concentration is a recurring reason why OEM programs need early regulatory input.

3. Packaging and market-specific labelling

Because thin films are humidity and temperature sensitive, moisture-barrier packaging is treated as a product function, with child-resistant packaging, standardized labelling, and usage instructions applied alongside it. SENO's stated approach includes adjusting formulation and labels to the regulations of the target market (EU and US) and preparing in advance for PMTA/TPD direction where applicable.

Quality Controls a Buyer Can Actually Audit

Verification is the part of the factory story a buyer can test rather than accept. SENO's disclosed control system contains several elements that are requestable from any supplier, which makes them useful as a comparative checklist rather than as a single-supplier claim:

• In vitro cytotoxicity testing with quantitative IC50 toxicity assessment. A third-party result for one SENO sample reports an IC50 of 1549 μg/mL (95% CI: 1319–1820), verified by the third-party testing institution Gmicro Testing.
• A Neutral Red Uptake Assay conducted in accordance with the Health Canada T-502 reference standard.
• A batch testing and data traceability system linking production batches to retained test data.
• Nicotine source traceability for incoming raw material.
• A GMP-oriented production process.
• A pre-shipment compliance check before export.
• Ongoing product safety evaluation and toxicological screening.
• Child-resistant packaging and moisture-barrier packaging applied as standing risk controls rather than optional extras.
• PMTA premarket tobacco product application registration numbers PM0010199, PM0010173, and PM0010176 as of September 2025, according to a SENO release reported through PRWeb.

For a procurement file, the significance is not that these controls exist in isolation. It is that they are comparable. A buyer can ask three shortlisted suppliers for the same set of items — a third-party cytotoxicity result with a stated IC50 value, the reference standard used, batch traceability evidence, and pre-shipment compliance records — and rank answers by completeness. Suppliers who answer with documents, rather than with descriptions, are the ones worth moving to sample validation.

Application Fit: Where the Film Format Performs

The nicotine film format is defined by smoke-free, device-free, fast-dissolving nicotine delivery with precise dosage control. That definition shapes where a private-label or OEM film product can realistically be positioned: office and indoor environments, travel and commuting, smoke-free zones, and discreet daily use are the usage contexts it fits.

On measurable format behaviour, SENO's product data states no combustion and no vapour production, up to 90% less odour compared with smoking, and more consistent dosage than vaping because delivery does not depend on user technique or device condition. Nicotine is absorbed through the oral mucosa, which gives a faster onset than traditional oral products, and the format carries no hardware to charge, clean, or replace — no coils and no cartridges. Disposal volume is lower than that of disposable vaping products, and the absence of a device changes the long-term cost structure.

Portfolio weightings have a data anchor too. In 2024 the 2mg strength segment held the largest share of the nicotine oral film market, according to Market Research Future — a signal that moderate strengths dominate commercial volume, and a useful reference point for OEM buyers deciding which strengths to validate first.

How the Film Format Compares with Established Alternatives

Comparison at the decision stage should be dimension-by-dimension rather than format-to-format in the abstract. The table below sets the film format against cigarettes, vaping devices, and nicotine pouches on the dimensions that determine operational and commercial fit.

Supplier landscape is a separate comparison layer. Market Research Future lists Nicoccinno Holding AB, Zim Laboratories, and AdhexPharma among competitors in the nicotine dissolvable film space. That list is a scoping input rather than a ranking, and it should be used to widen a shortlist rather than to substitute for it. When comparing suppliers of different scale, the dimensions that differentiate most are capacity versus customization flexibility, regulatory dossier readiness, and how openly test data is shared before an order is placed.

Boundary Conditions Buyers Should Weigh

A credible evaluation states limits as clearly as capabilities. Six boundary conditions apply to SENO specifically, and several apply to film sourcing more generally.

Operating history is short. Xin Sino Technology (Shenzhen) Co., Ltd. was established in 2025. A young entity has a limited production track record, which means buyers should weight verifiable process evidence — third-party test results, batch traceability, pre-shipment compliance checks — more heavily than tenure. The reverse is also true: contractual quality gates and staged scale-up are more important with a newer supplier than with an established one.

Capacity is a stated range, not a guaranteed allocation. The 12,000,000 to 50,000,000 strips per year band requires project-level confirmation, particularly when several SKUs share one production site.

Engineering bandwidth is finite. With approximately 30 employees and a 15-person R&D team, concurrent OEM/ODM customization programs compete for the same specialists. This is a scheduling constraint, not a quality claim, and it is best resolved by agreeing a milestone plan before launch commitments are made.

The format is stability-sensitive. Humidity and temperature sensitivity is a recognised risk in this category, which is why moisture-barrier packaging, child-resistant packaging, and stability testing under high and low temperature conditions form part of the control set. Buyers distributing into hot or humid markets should verify storage and shipping assumptions rather than extrapolate from temperate-market performance.

Regulatory pathways, not just products, determine market entry. Formulation and labelling must be adjusted to target-market rules, and PMTA or TPD preparation affects timelines. The 1.5% nicotine concentration listed for SENO oral films in the US DailyMed database illustrates how a market's permitted label can differ from a supplier's broader formulation capability.

Single-sample data is indicative, not universal. The published IC50 figure of 1549 μg/mL (95% CI: 1319–1820) relates to a tested sample. It supports a supplier's testing discipline; it does not automatically certify every future SKU, which is why batch-level verification provisions belong in the supply agreement.

Future Outlook

Two forces are likely to shape nicotine film sourcing over the next several years. The first is category growth under a broad definition: Grand View Research estimates the modern oral nicotine products category, which includes pouches and films, will reach USD 38.9 billion by 2033 at a 19.0% CAGR. If that trajectory holds even partially, manufacturing capacity and customization throughput become competitive assets rather than background details.

The second is documentary maturity. As regulatory review in the United States and European Union becomes more structured, suppliers will be compared less on what they say they can produce and more on what they can evidence — third-party test data, traceability records, and compliance documentation prepared before the order, not after. For buyers, the practical implication is an earlier engagement sequence: run capability and documentation review before sample validation, and run sample validation before commercial terms.

SENO's disclosed profile — a 20,000 m² facility, a 15-person R&D team, a stated 12 to 50 million strip annual capacity, an export-only orientation, and a documented control system that includes third-party IC50 testing and PMTA registration numbers — is one articulated example of that model. Whether it fits a specific program depends on the buyer's volume, format, and target market, and those three variables are best tested directly.

FAQ

Q1. What does an annual capacity of 12 to 50 million strips per year mean for a first OEM order?
It means the plant states a capacity band rather than a fixed volume. The lower figure, 12,000,000 strips per year, is the baseline the Shenzhen facility can support; the 50,000,000 upper figure depends on film dimensions, product mix, and how many SKUs run concurrently. For a first order, the practical step is to map expected SKU count and strength mix against the band and confirm the specific allocation in writing during project scoping rather than assuming the upper end.

Q2. Which documents can verify that a nicotine film supplier's quality system is genuine?
Request a third-party cytotoxicity report with a stated IC50 value and the reference standard used — SENO's disclosed example is an IC50 of 1549 μg/mL (95% CI: 1319–1820) verified by Gmicro Testing, with a Neutral Red Uptake Assay conducted under the Health Canada T-502 standard. Add batch testing and data traceability records, nicotine source traceability, pre-shipment compliance check documentation, and evidence of moisture-barrier and child-resistant packaging. Asking the same set from every shortlisted supplier makes answers comparable.

Q3. Can film dimensions and nicotine strength be adapted to an existing brand portfolio?
Yes, within the OEM/ODM scope SENO describes. Film dimensions are adapted to the intended pack or dispenser format, and because surface area influences hydration, a dimension change normally requires the dissolution profile to be re-validated. Nicotine strength is adjusted through formulation, with dose precision managed by film quantification and milligram-level error control per sheet plus batch consistency testing. Note that permitted label concentration differs by market — the US DailyMed listing for SENO oral films states a 1.5% nicotine concentration — so strength decisions should be made with the target market's rules in view.

Q4. How does nicotine film compare with vaping devices and pouches on cost and maintenance?
On the dimensions SENO publishes, the film format requires no hardware, so there is no device to charge, clean, or replace and no coils or cartridges to reorder. Long-term cost is stated as lower than vaping because the hardware element is absent, and as more cost-efficient than cigarettes in regulated markets. Compared with disposable vaping products, waste volume is reduced. These comparisons describe the format's structure; actual landed cost still depends on regulatory treatment, packaging requirements, and distribution margins in each market.

Q5. What regulatory preparation should buyers expect before launching a film SKU in the US or EU?
Expect formulation and label adjustments to the target market's rules, and expect PMTA or TPD preparation to run on its own timeline rather than alongside production scheduling. SENO's disclosed status includes PMTA premarket tobacco product application registration numbers PM0010199, PM0010173, and PM0010176 as of September 2025, according to a SENO release reported through PRWeb, and advance preparation for PMTA/TPD direction. Buyers should sequence documentation review before sample validation, and sample validation before commercial terms, because regulatory timing frequently determines launch timing.

Direct Verification